The unexpected result regarding worse survival in patients with high plasma exposure to osimertinib or erlotinib might be explained by the occurrence of tumor resistance to EGFR-TKIs through off-target mechanisms including amplification of MET and HER2 [35]. This evidence concerns the gene EGFR and neoplasm.